The Strategic Transformation Of Qingdao Growful Pharmaceutical Under The Background Of New Medical Reform

The new medical reform program will be incorporated into the pharmaceutical industry,the scope of health care reform,which is one of the salient features that distinguish it from conventional medical reform policies,the introduction and implementation of a series of reform measures related to the pharmaceutical industry, will promote the improvement of China’s pharmaceutical industry concentration, and medicine Reconstruction of the market capacity increases and flow of the market structure, development opportunities and challenges exist. Which require pharmaceutical companies to recognize the market situation, and the search for effective ways of enterprise’s development.Qingdao Growful pharmaceutical is engaged in cutting-edge research in life sciences,after many years of accumulation, now it has a strong R & D capabilities and improve production capacity,with independent intellectual property rights of medicines, health products, nutrition food,beauty care products,medical devices and more than dozens of recycled products. while group also has commercial points pin company and chain business pharmacy,covers medicine development, and production,and distribution of near full industry chain.After analyzing the situation and the premise of Chinese medicine industry to resolve profound medical and health system policies, through the industry in Qingdao relevant collected data,collated and analyzed, reviewed the relevant situation and development status Qingdao Growful Pharmaceutical at the same time, use of "Porter’s five forces model" Qingdao Growful pharmaceutical development strategies,SWOT analysis of Qingdao Growful medicine for diagnosis,and to explore development strategy of the industry in Qingdao under the new health care system reform policy background. This article aims for the provide the theoretical background of the Pharmaceutical industry in Qingdao under the new health care reform and provide scientific decision-making reference for other pharmaceutical companies developing new medical reform under the background of peers.